Cladribine

Last updated
Cladribine
Cladribine.svg
Clinical data
Trade names Leustatin, Mavenclad, others [1]
Other names2-Chlorodeoxyadenosine; 2-Chloro-2'-deoxyadenosine; 2-CdA
AHFS/Drugs.com Monograph
MedlinePlus a693015
License data
Pregnancy
category
  • AU:D
Routes of
administration 		Intravenous, subcutaneous (liquid), by mouth (tablet)
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 100% (i.v.); 37 to 51% (orally) [4]
Protein binding 25% (range 5-50%); [5] up to 20% (orally) [6]
Metabolism Mostly via intracellular kinases; 15-18% is excreted unchanged. [5]

Intravenous and subcutaneous bolus injection: 15-18% is excreted unchanged

After oral administration, 25% (±21%) of dose is excreted unchanged in urine and 3.8% as a metabolite.

Contents

[6]
Elimination half-life Approximately 10 hours after both intravenous infusion and subcutaneous bolus injection ranging from 5.6 to 7.6 hours [5] and 18.4 to 19.7 hours after oral administration, indicative of different elimination phases.
Excretion Urinary [5]
Identifiers
  • 5-(6-Amino-2-chloro-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.164.726 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C10H12ClN5O3
Molar mass 285.69 g·mol−1
3D model (JSmol)
  • Clc1nc(c2ncn(c2n1)[C@@H]3O[C@@H]([C@@H](O)C3)CO)N
  • InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1 Yes check.svgY
  • Key:PTOAARAWEBMLNO-KVQBGUIXSA-N Yes check.svgY
   (verify)

Cladribine, sold under the brand name Leustatin, among others, is a medication used to treat hairy cell leukemia (leukemic reticuloendotheliosis) and B-cell chronic lymphocytic leukemia. [7] [8] Cladribine, sold under the brand name Mavenclad, is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis. [9]

Cladribine is a purine analogue that selectively targets and suppresses lymphocytes implicated in the underlying pathogenesis of multiple sclerosis and B-cell leukaemia. [10] [6] [11] Chemically, it mimics the nucleoside deoxyadenosine. However, unlike deoxyadenosine, it is relatively resistant to breakdown by the enzyme adenosine deaminase, which causes it to accumulate in targeted cells and interfere with the cell's ability to process DNA. [6] Cladribine is taken up by cells via transporter proteins. Once inside a cell, cladribine undergoes phosphorylation by the enzyme deoxycytidine kinase (DCK) to produce mononucleotide 2-chlorodeoxyadenosine 5’monophosphate (2-CdAMP), which is subsequently phosphorylated to the triphosphorylated active compound 2-chlorodeoxyadenosine 5’triphosphate (2-CdATP). Activated cladribine is incorporated into cellular DNA, which triggers apoptosis. Accumulation of cladribine into cells is dependent on the ratio of DCK and 5'-nucleotidase (5’-NT), which breaks down and inactivates the compound. This ratio differs between cell types, with high levels in T and B lymphocytes, resulting in selective targeting of these cells. In contrast, DCK:5'NT is relatively low in other cell types, thus sparing numerous non-haematological cells. [10] [6]

It is on the World Health Organization's List of Essential Medicines. [12]

Medical uses

Cladribine is used as a first- and second-line treatment for symptomatic hairy cell leukemia and for B-cell chronic lymphocytic leukaemia, and is administered by intravenous or subcutaneous infusion. [8] [13] Some investigators have used the parenteral formulation orally to treat patients with hairy cell leukemia. About 37–51% of oral cladribine is bioavailable orally. [6] It is used, often in combination with other cytotoxic agents, to treat various kinds of histiocytosis, including Erdheim–Chester disease [14] and Langerhans cell histiocytosis. [15]

Following EMA approval of cladribine tablets for the treatment of adult patients with highly active relapsing-remitting multiple sclerosis in 2017, as of July 2020, cladribine tablets have gained marketing authorisation in over 75 countries. [16] In 2019, cladribine tablets were approved by the FDA for the treatment of relapsing forms of multiple sclerosis, to include relapsing-remitting disease and active secondary progressive disease, in adult patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of multiple sclerosis. [16] [17]

Cladribine may cause foetal harm when administered to a pregnant woman and is listed by the FDA as pregnancy category D; safety and efficacy in children has not been established. [13]

Mechanism of action

As a purine analogue, cladribine is taken up into rapidly proliferating cells, including B and T lymphocytes, to be incorporated into DNA synthesis. Chemically, it mimics nucleoside adenosine; however, unlike adenosine, cladribine has a chlorine molecule at position 2, which renders it partially resistant to breakdown by adenosine deaminase. This causes it to accumulate in cells and interfere with the targeted cell's ability to process DNA. [6] [10]

Cladribine is taken up by specific nucleoside transporter proteins. Once inside a cell, cladribine undergoes phosphorylation by the enzyme deoxycytidine kinase (DCK) to produce mononucleotide 2-chlorodeoxyadenosine 5’monophosphate (2-CdAMP), which is subsequently phosphorylated to the triphosphorylated active compound, 2-chlorodeoxyadenosine 5’triphosphate (2-CdATP). [10] [6]

Activated cladribine is incorporated into the DNA synthesis pathway, where it disrupts DNA repair and synthesis, resulting in an accumulation of DNA strand breaks [10] [6] [18] This is followed by the activation of transcription factor p53, the release of cytochrome c from mitochondria and eventual programmed cell death (apoptosis). [18] This process occurs over approximately 2 months, with a peak level of cell depletion 4–8 weeks after treatment. [19]

Another family of enzymes, the 5'-nucleotidase (5'-NT) family, is also capable of dephosphorylating cladribine, making it inactive. The most important subtypes of this group appear to be cytosolic 5'-NT, c-5NCT1A and c-NT1B, which are cytosolically active and specific for purine analogues. [20]

Accumulation of cladribine into cells is dependent on the ratio of DCK and 5'-NT. This ratio differs between cell types, with high levels in T and B lymphocytes, making them particularly susceptible to cell death. The cells with the highest ratios are B cells, especially germinal centre and naïve B cells. This helps to explain which B cells are more vulnerable to cladribine-mediated apoptosis. DCK is the rate-limiting enzyme for conversion of the cladribine prodrug into its active triphosphate form, leading to the selective depletion of dividing and non-dividing T and B lymphocytes. In contrast, the DCK:5'-NT ratio is relatively low in other cell types, thus sparing numerous non-hematologic cells. [10] [6] [20]

In multiple sclerosis, cladribine's effectiveness may be due to depletion of B cells, in particular memory B cells. [21] In the pivotal phase 3 clinical trial of oral cladribine in multiple sclerosis, CLARITY, cladribine selectively depleted 80% of peripheral B cells, compared to only 40–45% of CD4+ T cells and 15‒30% CD8+ T cells. [22] More recently, cladribine has been shown to induce long term, selective suppression of certain subtypes of B cells, especially memory B cells. [20]

Although cladribine is selective for B cells, the long-term suppression of memory B cells, which may contribute to its effect in multiple sclerosis, is not explained by gene or protein expression. Instead, cladribine appears to deplete the entire B cell department, but while naïve B cells rapidly move from lymphoid organs, the memory B cell pool repopulates slowly from the bone marrow. Both hairy cell leukemia and B-cell chronic lymphocytic leukaemia are types of B cell blood cancers.

History in hairy cell leukemia

Ernest Beutler and Dennis A. Carson had studied adenosine deaminase deficiency and recognised that because the lack of adenosine deaminase led to the destruction of B cell lymphocytes, a drug designed to inhibit adenosine deaminase might be useful in lymphomas. Carson then synthesised cladribine, and through clinical research at Scripps starting in the 1980s, Beutler tested it as intravenous infusion and found it was especially useful to treat hairy cell leukemia. No pharmaceutical companies were interested in selling the drug because hairy cell leukemia was an orphan disease, so Beutler's lab synthesised and packaged it and supplied it to the hospital pharmacy; the laboratory also developed a test to monitor blood levels. This was the first treatment that led to prolonged remission of hairy cell leukemia, which was previously untreatable. [23] : 14–15 

In February 1991, Scripps began a collaboration with Johnson & Johnson to bring intravenous cladribine to market, and by December of that year, Johnson & Johnson had filed a new drug application; cladribine was approved by the FDA in 1993 for hairy cell leukemia as an orphan drug, [24] and was approved in Europe later that year. [25] : 2 

The subcutaneous formulation was developed in Switzerland in the early 1990s and it was commercialised by Lipomed GmbH in the 2000s. [25] : 2  [26]

Safety profile of cladribine in hairy cell leukemia

Injectable cladribine suppresses the body's ability to make new lymphocytes, natural killer cells, and neutrophils (called myelosuppression); data from hairy cell leukemia studies showed that about 70% of people taking the drug developed dangerously low levels of white blood cells and about 30% developed infections and some of those progressed to septic shock; about 40% of people taking the drug had fewer red blood cells and became severely anaemic; and about 10% of people had too few platelets. [13] At the dosage used to treat hairy cell leukemia in two clinical trials, 16% of people had rashes and 22% had nausea, the nausea generally did not lead to vomiting. [13]

History in multiple sclerosis

In the mid-1990s, Beutler, in collaboration with Jack Sipe, a neurologist at Scripps Institute, ran several clinical trials exploring the utility of cladribine in multiple sclerosis, based on the drug's immunosuppressive effects. Sipe's insight into multiple sclerosis, and Beutler's interest in multiple sclerosis due to his sister having the disease, initiated a very productive collaboration. [27] Ortho-Clinical, a subsidiary of Johnson & Johnson, filed a new drug application for cladribine for multiple sclerosis in 1997 but withdrew it in the late 1990s after discussion with the FDA proved that more clinical data would be needed. [27]

Ivax acquired the rights for oral administration of cladribine to treat multiple sclerosis from Scripps in 2000, [28] and partnered with Serono in 2002. [29] Ivax was acquired by Teva in 2006, [30] [31] and Merck KGaA acquired control of Serono's drug business in 2006. [32]

An oral formulation of the drug with cyclodextrin was developed [33] : 16  by Ivax and Serono, and then Merck KGaA conducted clinical trials. Merck KGaA submitted an application to the European Medicines Agency in 2009, which was rejected in 2010, and an appeal was denied in 2011. [33] : 4–5  Likewise Merck KGaA's new drug application with the FDA rejected in 2011. [34]

The ratio of benefit to harm was not clear to regulators, and further studies were requested to address concerns related to severe lymphopenia and cancer cases observed during pivotal trials. [33] : 54–55  Clinical studies of multiple sclerosis were still ongoing at the time of the rejections, and Merck KGaA committed to completing them. [34] A meta-analysis of data from clinical trials comparing the risk of cancer and other disease-modifying therapies showed that cladribine tablets did not increase the risk of cancer at the doses used in the initial clinical trials. [35]

Based on the supporting data from the completed clinical trials that confirmed no increased risk of cancer, Merck announced it would again seek regulatory approval. [36] In 2016, the EMA accepted its application for review. [37] On June 22, 2017, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the treatment of relapsing forms of multiple sclerosis. [38]

Cladribine tablets were later approved in Europe, in August 2017, for highly active relapsing-remitting multiple sclerosis, and has since been approved by the FDA for the treatment of relapsing-remitting and secondary progressive multiple sclerosis in the US. [39]

Use in multiple sclerosis

As per the EU label, cladribine tablets are indicated for the treatment of adult patients with highly active relapsing multiple sclerosis as defined by clinical or imaging features: (i) patients with a relapse in the previous year and at least one T1 Gd+ lesion or 9 or more T2 lesions, while on another disease-modifying therapies or (ii) patients with two or more relapses in the previous year, whether on disease-modifying treatment or not. [9]

Two main approaches to multiple sclerosis treatment maintenance therapy are used – immunomodulation and immunosuppression and alternatively, immune reconstitution therapy. Classified as the latter, cladribine tablets are administered intermittently as a short treatment course without continuous immunosuppression. In contrast to maintenance therapies, clinical efficacy extends beyond the dosing period. [40] [41] [42]

Cladribine tablets are administered as 2 courses separated by 1 year (a maximum of 20 days of treatment). The recommended cumulative dose is 3.5 mg/kg weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. Each treatment course consists of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective treatment year. Each treatment week consists of 4 or 5 days on which a patient receives 10 mg or 20 mg (1 or 2 tablets) as a single daily dose based on body weight. [9]

Before initiating treatment with cladribine tablets, blood tests, MRI and infection screening must be performed. Due to an increased risk of herpes zoster with cladribine tablets, patients who are antibody-negative for varicella zoster virus are recommended to be vaccinated before starting treatment. Treatment should not be initiated within 4 to 6 weeks of receiving a live or attenuated live vaccine because of a risk of active infection. Vaccination with live or attenuated live vaccines should also be avoided during and after treatment, but can be considered when lymphocyte counts have recovered to ≥1000 cells/mm3. [9]

Following completion of the two treatment courses, no further treatment or additional monitoring is required. [9]

The use of cladribine tablets is contraindicated in pregnant women, and women of childbearing potential must use effective contraception to prevent pregnancy during treatment and 6 months after receiving the last dose. [9]

Efficacy of cladribine tablets in multiple sclerosis

Clinical trial results have shown that cladribine tablets can be an effective treatment for highly active, relapsing forms of multiple sclerosis, with significant clinical benefits in relapse rate, disability progression, and radiological measures. [43] Compared with placebo, patients who received cladribine tablets (3.5 mg/kg) in the CLARITY study had a 58% reduction in annualized relapse rate [44] and 47% of patients showed no evidence of disease activity at 2 years. [45] Clinical improvements can be observed at Week 24 of treatment, [45] [46] [47] and benefits may be sustained up to 4 years, beyond the 2-year dosing period and recovery of total lymphocytes. [43] [48] [49] Post-hoc analyses of clinical trial data showed that 89% of patients remained free from disability progression two years after treatment. [50]

Further analyses of a subgroup of patients in the CLARITY study who had very active multiple sclerosis showed a 67% reduction in relapse rates and an 82% reduction in disability progression in those treated with cladribine tablets. Similarly, clinical improvements were seen in lesion burden on MRI scans in this population. [51]

Studies evaluating the treatment effects of cladribine tablets across a spectrum of baseline demographics and disease characteristics showed that the relative risk of relapse was significantly reduced compared with placebo, irrespective of previous treatment experience. [52]

Furthermore, treatment with cladribine tablets has been shown to significantly reduce the rate of brain atrophy in patients with highly active relapsing-remitting multiple sclerosis. This reduction correlated with a reduced risk in disability progression in a retrospective analysis. [53]

In clinical trials, higher cumulative doses of cladribine tablets did not result in further improvement in efficacy nor did additional courses after the 2-year treatment period, but was associated with a higher incidence of Grade 3 and Grade 4 lymphopenia. [9] [43]

Safety profile of cladribine tablets in multiple sclerosis

Cladribine tablets target the cells of the adaptive immune system with minimal impact on innate immune cells. Although the exact mechanism by which cladribine exerts its therapeutic effect is not fully elucidated, it is proposed to have a transient effect on B and T lymphocyte depletion, interrupting the cascade of immune events central to multiple sclerosis. As a result, a reduction in lymphocyte count (lymphopenia) may be reported following treatment. [9] In clinical trials, lymphocyte levels above Grade 0 (≥1000 cells/mm3) and Grade 1 (<1000–800 cells/mm3) were maintained in most patients, with levels continuing to improve after the 2-year dosing period. [48] Less than 1% of patients developed Grade 4 lymphopenia (<200 cells/mm3). It is important that patients with lymphocyte counts below 500 cells/mm3 should be actively monitored for signs suggestive of infection and that anti-infective treatments are given to at-risk patients. [9] [54]

Despite the initial reduction in lymphocyte counts following treatment, studies showed the overall risk of infection in patients receiving cladribine tablets was comparable to those who received placebo, except for herpes zoster infection. [54] Due to this increased risk, it is recommended that patients are screened for varicella zoster virus and antibody-negative patients are vaccinated prior to receiving treatment. [9] In an analysis of post-approval data, as of 2020, no new infection safety signals were observed in over 18,000 patients. [55]

Progressive multifocal leukoencephalopathy has been reported in patients with hairy cell leukemia treated with parenteral cladribine. [9] However, in up to 10 years of follow-up of patients receiving cladribine tablets for multiple sclerosis, no cases of progressive multifocal leukoencephalopathy have been observed; baseline MRI must be performed prior to initiating treatment. [9]

In clinical trials, malignancies were observed more frequently in patients treated with cladribine tablets compared with patients who received placebo. Compared with a matched reference population from the Global Cancer Observatory database, cladribine tablets had no increased risk of malignancy in long-term real-world evidence data. [9] [54]

Research

Cladribine has been studied as part of a multidrug chemotherapy regimen for drug-resistant T-cell prolymphocytic leukaemia. [56]

Related Research Articles

<span class="mw-page-title-main">Interferon beta-1a</span> Cytokine in the interferon family

Interferon beta-1a is a cytokine in the interferon family used to treat multiple sclerosis (MS). It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. Some research indicates that interferon injections may result in an 18–38% reduction in the rate of MS relapses.

Daclizumab is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.

<span class="mw-page-title-main">Hairy cell leukemia</span> Hematological malignancy

Hairy cell leukemia is an uncommon hematological malignancy characterized by an accumulation of abnormal B lymphocytes. It is usually classified as a subtype of chronic lymphocytic leukemia (CLL). Hairy cell leukemia makes up about 2% of all leukemias, with fewer than 2,000 new cases diagnosed annually in North America and Western Europe combined.

<span class="mw-page-title-main">Mitoxantrone</span> Chemical compound

Mitoxantrone is an anthracenedione antineoplastic agent.

Interferon beta-1b is a cytokine in the interferon family used to treat the relapsing-remitting and secondary-progressive forms of multiple sclerosis (MS). It is approved for use after the first MS event. Closely related is interferon beta 1a, also indicated for MS, with a very similar drug profile.

<span class="mw-page-title-main">Alemtuzumab</span> Medication

Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment. It is given by injection into a vein.

Lymphocytopenia is the condition of having an abnormally low level of lymphocytes in the blood. Lymphocytes are a white blood cell with important functions in the immune system. It is also called lymphopenia. The opposite is lymphocytosis, which refers to an excessive level of lymphocytes.

<span class="mw-page-title-main">Bruton's tyrosine kinase</span> Kinase that plays a role in B cell development

Bruton's tyrosine kinase, also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the BTK gene in humans. BTK plays a crucial role in B cell development.

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS). Several therapies for it exist, although there is no known cure.

<span class="mw-page-title-main">CD22</span> Lectin molecule

CD22, or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins. It is found on the surface of mature B cells and to a lesser extent on some immature B cells. Generally speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases.

<span class="mw-page-title-main">Ofatumumab</span> Medication

Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. It is sold by Novartis under license from Genmab.

<span class="mw-page-title-main">CD52</span> Protein-coding gene found in humans

CAMPATH-1 antigen, also known as cluster of differentiation 52 (CD52), is a glycoprotein that in humans is encoded by the CD52 gene.

<span class="mw-page-title-main">Laquinimod</span> Chemical compound

Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS) and Huntington's disease.

Atacicept is a recombinant fusion protein designed to inhibit B cells, thereby suppressing autoimmune disease. The designer protein combines the binding site for two cytokines that regulate maturation, function, and survival of B cells - B-lymphocyte stimulator (BLyS) and A proliferation-inducing ligand (APRIL), with the constant region of immunoglobin. Atacicept blocks activation of B cells by the tumor necrosis factor receptor superfamily member 13B, a transmembrane receptor protein found predominantly on the surface of B cells. Like the monoclonal antibody belimumab, atacicept blocks the binding of BLyS, but it also blocks APRIL. Binding of these TACI ligands induces proliferation, activation, and longevity of B cells and thus their production of autoantibodies. Atacicept is thought to selectively impair mature B cells and plasma cells with less impact on progenitor cells and memory B cells.

Ublituximab, sold under the brand name Briumvi, is an immunomodulator used for the treatment of multiple sclerosis. It is a CD20-directed cytolytic monoclonal antibody.

<span class="mw-page-title-main">Idelalisib</span> Chemical compound

Idelalisib, sold under the brand name Zydelig, is a medication used to treat certain blood cancers. Idelalisib acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase. It was developed by Gilead Sciences. It is taken orally.

<span class="mw-page-title-main">Ozanimod</span> Medication

Ozanimod, sold under the brand name Zeposia, is an immunomodulatory medication for the treatment of relapsing multiple sclerosis and ulcerative colitis. It acts as a sphingosine-1-phosphate receptor (S1PR) agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation.

<span class="mw-page-title-main">Siponimod</span> Chemical compound

Siponimod, sold under the brand name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis (MS). It is intended for once-daily oral administration.

There are several ways for pharmaceuticals for treating multiple sclerosis (MS) to reach the market.

<span class="mw-page-title-main">Shimon Slavin</span> Israeli professor of medicine

Shimon Slavin is an Israeli professor of medicine. Slavin pioneered the use of immunotherapy mediated by allogeneic donor lymphocytes and innovative methods for stem cell transplantation for the cure of hematological malignancies and solid tumors, and using hematopoietic stem cells for induction of transplantation tolerance to bone marrow and donor allografts.

References

  1. ↑ "Cladribine". Drugs.com. 28 February 2020. Retrieved 4 March 2020.
  2. ↑ "Neurological therapies". Health Canada . 9 May 2018. Retrieved 13 April 2024.
  3. ↑ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 Oct 2023.
  4. ↑ Liliemark J (February 1997). "The clinical pharmacokinetics of cladribine". Clinical Pharmacokinetics. 32 (2): 120–131. doi:10.2165/00003088-199732020-00003. PMID   9068927. S2CID   32926069.
  5. 1 2 3 4 "PRODUCT INFORMATION LITAK© 2 mg/mL solution for injection" (PDF). TGA eBusiness Services. St Leonards, Australia: Orphan Australia Pty. Ltd. 10 May 2010. Retrieved 27 November 2014.
  6. 1 2 3 4 5 6 7 8 9 10 Giovannoni G (October 2017). "Cladribine to Treat Relapsing Forms of Multiple Sclerosis". Neurotherapeutics. 14 (4): 874–887. doi:10.1007/s13311-017-0573-4. PMC   5722776 . PMID   29168160.
  7. ↑ "European Medicines Agency - - Litak". www.ema.europa.eu. 17 September 2018.
  8. 1 2 "Leustat Injection. - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. Archived from the original on 2017-10-03. Retrieved 2016-08-19.
  9. 1 2 3 4 5 6 7 8 9 10 11 12 13 "Mavenclad EU SmPC" (PDF). European Medicines Agency. February 2021.
  10. 1 2 3 4 5 6 Leist TP, Weissert R (2011). "Cladribine: mode of action and implications for treatment of multiple sclerosis". Clinical Neuropharmacology. 34 (1): 28–35. doi:10.1097/WNF.0b013e318204cd90. PMID   21242742. S2CID   43201228.
  11. ↑ Jain P, Pemmaraju N, Ravandi F (June 2014). "Update on the biology and treatment options for hairy cell leukemia". Current Treatment Options in Oncology. 15 (2): 187–209. doi:10.1007/s11864-014-0285-5. PMC   4198068 . PMID   24652320.
  12. ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl: 10665/371090 . WHO/MHP/HPS/EML/2023.02.
  13. 1 2 3 4 "Cladribine- cladribine injection". DailyMed. 31 December 2019. Retrieved 4 March 2020.
  14. ↑ "Erdheim-Chester Disease". Histiocytosis Association. Archived from the original on 6 June 2019.
  15. ↑ Aricò M (June 2016). "Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy". British Journal of Haematology. 173 (5): 663–670. doi: 10.1111/bjh.13955 . PMID   26913480. The combination of cytarabine and cladribine is the current standard for second-line therapy of refractory cases with vital organ dysfunction.
  16. 1 2 Rammohan K, Coyle PK, Sylvester E, Galazka A, Dangond F, Grosso M, Leist TP (December 2020). "The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review". Drugs. 80 (18): 1901–1928. doi:10.1007/s40265-020-01422-9. PMC   7708385 . PMID   33247831.
  17. ↑ Jamroz-Wiśniewska A, Bełtowski J, Wójcicka G, Bartosik-Psujek H, Rejdak K (2020). "Cladribine Treatment Improved Homocysteine Metabolism and Increased Total Serum Antioxidant Activity in Secondary Progressive Multiple Sclerosis Patients". Oxidative Medicine and Cellular Longevity. 2020: 1654754. doi: 10.1155/2020/1654754 . PMC   7103043 . PMID   32256946.
  18. 1 2 Johnston JB (June 2011). "Mechanism of action of pentostatin and cladribine in hairy cell leukemia". Leukemia & Lymphoma. 52 (Suppl 2): 43–45. doi:10.3109/10428194.2011.570394. PMID   21463108. S2CID   207508023.
  19. ↑ Beutler E, Piro LD, Saven A, Kay AC, McMillan R, Longmire R, et al. (1991). "2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside". Leukemia & Lymphoma. 5 (1): 1–8. doi:10.3109/10428199109068099. PMID   27463204.
  20. 1 2 3 Ceronie B, Jacobs BM, Baker D, Dubuisson N, Mao Z, Ammoscato F, et al. (May 2018). "Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells". Journal of Neurology. 265 (5): 1199–1209. doi:10.1007/s00415-018-8830-y. PMC   5937883 . PMID   29550884.
  21. ↑ Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K (February 2017). "Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis". eBioMedicine. 16: 41–50. doi:10.1016/j.ebiom.2017.01.042. PMC   5474520 . PMID   28161400.
  22. ↑ Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K (July 2017). "Both cladribine and alemtuzumab may effect MS via B-cell depletion". Neurology. 4 (4): e360. doi:10.1212/NXI.0000000000000360. PMC   5459792 . PMID   28626781.
  23. ↑ Lichtman MA (2012). "Biographical Memoir: Ernest Beutler 1928–2008" (PDF). National Academy of Sciences.
  24. ↑ Staff (8 March 1993). "Ortho Biotech's Leustatin For Hairy Cell Leukemia". The Pink Sheet. Archived from the original on 3 October 2017.
  25. 1 2 "Litak EMA package: Scientific Discussion" (PDF). Europeans Medicines Agency. 2004.
  26. ↑ "Litak: Background Information on the Procedure" (PDF). Europeans Medicines Agency. 2004.
  27. 1 2 Sauter E, Ono M. "A potential new MS treatment's long and winding road". News & Views - Scripps Research Institute.
  28. ↑ "Ivax to Develop Cladribine for Multiple Sclerosis". Reuters. 4 December 2000.
  29. ↑ Sargent C (31 October 2002). "Serono Purchases Rights To Experimental MS Drug". Dow Jones Newswires in the Wall Street Journal.
  30. ↑ Bayot J (26 July 2005). "Teva to Acquire Ivax, Another Maker of Generic Drugs". New York Times.
  31. ↑ "Teva Completes Acquisition of Ivax". Teva Press Release. 2006. Archived from the original on 2019-12-18. Retrieved 2016-08-21.
  32. ↑ Staff (21 September 2006). "Merck KGaA to acquire Serono". First Word Pharma.
  33. 1 2 3 "Withdrawal Assessment Report for Movectro" (PDF). Europeans Medicines Agency. 2011. Procedure No. EMEA/H/C/001197
  34. 1 2 Gever J (22 June 2011). "Merck KGaA Throws in Towel on Cladribine for MS".
  35. ↑ Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, et al. (December 2015). "No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine". Neurology. 2 (6): e158. doi:10.1212/nxi.0000000000000158. PMC   4592538 . PMID   26468472.
  36. ↑ "Four years after a transatlantic slapdown, Merck KGaA will once again seek cladribine OK". Fierce Biotech.
  37. ↑ "Merck Receives European Medicines Agency Acceptance for Review of Marketing Authorization Application for Cladribine Tablets". PR News Wire. 18 July 2016.
  38. ↑ Merck. "Cladribine Tablets Receives Positive CHMP Opinion for Treatment of Relapsing Forms of Multiple Sclerosis". www.prnewswire.co.uk. Retrieved 2017-08-22.
  39. ↑ "Cladribine approved in Europe". Merck Press Release. 25 August 2017.
  40. ↑ Sorensen PS, Sellebjerg F (2019). "Pulsed immune reconstitution therapy in multiple sclerosis". Therapeutic Advances in Neurological Disorders. 12: 1756286419836913. doi:10.1177/1756286419836913. PMC   6440030 . PMID   30944586.
  41. ↑ Giovannoni G (June 2018). "Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm". Current Opinion in Neurology. 31 (3): 233–243. doi:10.1097/WCO.0000000000000561. PMID   29634596. S2CID   4736668.
  42. ↑ Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K (July 2017). "Both cladribine and alemtuzumab may effect MS via B-cell depletion". Neurology: Neuroimmunology & Neuroinflammation. 4 (4): e360. doi:10.1212/NXI.0000000000000360. PMC   5459792 . PMID   28626781.
  43. 1 2 3 Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, et al. (October 2018). "Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study". Multiple Sclerosis. 24 (12): 1594–1604. doi: 10.1177/1352458517727603 . PMID   28870107. S2CID   1910070.
  44. ↑ Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, et al. (February 2010). "A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis". The New England Journal of Medicine. 362 (5): 416–426. doi: 10.1056/NEJMoa0902533 . PMID   20089960.
  45. 1 2 Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, et al. (April 2011). "Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis". The Lancet. Neurology. 10 (4): 329–337. doi:10.1016/S1474-4422(11)70023-0. PMID   21397565. S2CID   20149620.
  46. ↑ Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, et al. (April 2013). "MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study". Journal of Neurology. 260 (4): 1136–1146. doi:10.1007/s00415-012-6775-0. PMID   23263473. S2CID   8934723.
  47. ↑ Schippling S (2018). "CLARITY: An analysis of severity and frequency of relapses in patients with RRMS treated with cladribine tablets or placebo". Ectrims: P549.
  48. 1 2 Comi G, Cook S, Giovannoni G, Rieckmann P, Sørensen PS, Vermersch P, et al. (April 2019). "Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis". Multiple Sclerosis and Related Disorders. 29: 168–174. doi: 10.1016/j.msard.2019.01.038 . PMID   30885375. S2CID   83461539.
  49. ↑ Giovannoni G (2017). "Effect of cladribine tablets on relapse rates and the proportions qualified relapse-free in patients with multiple sclerosis: analysis of the CLARITY and CLARITY extension studies". EAN: P0542.
  50. ↑ Giovannoni G, Rammohan K, Cook S, Soelberg-Sørensen P, Vermersch P, Keller B, et al. (2018). "An exploratory analysis of the efficacy of cladribine tablets 3.5mg/kg in patients with relapsing multiple sclerosis stratified according to age above and below 45 years in the CLARITY study". Ectrims: P1204. Archived from the original on 2021-07-17. Retrieved 2021-07-14.
  51. ↑ Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan KW, Rieckmann P, Comi G, et al. (May 2019). "Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study". Multiple Sclerosis. 25 (6): 819–827. doi:10.1177/1352458518771875. PMC   6460686 . PMID   29716436.
  52. ↑ Rammohan K, Giovannoni G, Comi G, Cook S, Rieckmann P, Soelberg Sørensen P, et al. (January 2012). "Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study". Multiple Sclerosis and Related Disorders. 1 (1): 49–54. doi:10.1016/j.msard.2011.08.006. PMID   25876451.
  53. ↑ De Stefano N, Giorgio A, Battaglini M, De Leucio A, Hicking C, Dangond F, et al. (February 2018). "Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets". Multiple Sclerosis. 24 (2): 222–226. doi:10.1177/1352458517690269. PMC   5818021 . PMID   28140753.
  54. 1 2 3 Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, et al. (April 2019). "Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis". Multiple Sclerosis and Related Disorders. 29: 157–167. doi: 10.1016/j.msard.2018.11.021 . PMID   30885374. S2CID   81873347.
  55. ↑ Giovannoni G (2020). "A965". Actrims-Ectrims: A965.
  56. ↑ Hasanali ZS, Saroya BS, Stuart A, Shimko S, Evans J, Vinod Shah M, et al. (June 2015). "Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia". Science Translational Medicine. 7 (293): 293ra102. doi:10.1126/scitranslmed.aaa5079. PMC   4807901 . PMID   26109102.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.